Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752050 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows
A Phase 3 study, sponsored by Mentor Worldwide.
- Completed
- Registry status
- Phase 3
- Development phase
- 699
- Enrollment target
NCT00752050 is a Phase 3 study that has completed, run by Mentor Worldwide. The registered enrollment target is 699 participants.
The verdict
NCT00752050, a Phase 3 study, has completed, sponsored by Mentor Worldwide.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 699 participants
- Enrollment target
Study Summary
The overall purpose of this study is to evaluate the safety and effectiveness of repeat treatment of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
Interventions
- DRUG Mentor Purified Toxin Botulinum Toxin Type A
- DRUG Preservative-free Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 699 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752050
The ClinicalTrials.gov registry entry for NCT00752050 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mentor Worldwide, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mentor Purified Toxin Botulinum Toxin Type A is the first listed.
NCT00752050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752050 about?
NCT00752050 is a clinical study titled "Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows". The overall purpose of this study is to evaluate the safety and effectiveness of repeat treatment of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
What is the current status of trial NCT00752050?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 699 participants. The study started on 2007-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00752050?
The interventions under investigation include: Mentor Purified Toxin Botulinum Toxin Type A (DRUG), Preservative-free Saline (DRUG).
Who is sponsoring clinical trial NCT00752050?
This trial is sponsored by Mentor Worldwide, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.